About Us

About Us
Our Science
Commercial Opportunities
Latest News

Bone Marrow Transplantation (2023)

Technical Reports:
Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy


GreenJay Therapeutics, Inc. (GreenJay) is a clinical-stage pharmaceutical 

company based in Conroe (Houston), Texas, focused on reformulation of drugs

 with significant deficiencies. The Company has developed a new formulation

 of  IV busulfan as a pretreatment related to stem cell transplantation. Current

 IV  formulations of busulfan on the market contain a toxic excipient whereas

the new formulation developed by GreenJay does not. This new formulation of IV Busulfan, Bulanta™, may

be approved by the FDA without the requirement for additional clinical trials.